Abstract
Crohn's disease (CD) treatments and associated adverse events (AEs) can be burdensome for patients. However, specific values which quantify the impact on health-related quality of life (HRQL) for economic evaluation are lacking. This study aimed to elicit health utility values for AEs related to biologic treatment and surgical complications for CD in the UK. Health states were developed by literature review and interviews with CD patients (n=6) and gastroenterologists (n=3). Draft health states were validated in cognitive debrief interviews with patients (n=4) and gastroenterologists (n=2). Treatment AEs were described with moderate-severe CD (reference state) and included hypersensitivity, injection site reactions, serious infection, lymphoma, and tuberculosis. Surgical complications were described following bowel surgery (reference state) and included anastomotic leak, wound infection, prolonged ileus/bowel obstruction, and intra-abdominal abscess. Health states were valued by 100 members of the general public who completed background questions, EQ-5D-3L, visual analogue scale rating task and time trade-off (TTO) interviews. The mean TTO value for reference states 'moderate to severe CD' and 'bowel surgery' were 0.70 (SD=0.28...Continue Reading
References
Nov 5, 1990·Health Policy·UNKNOWN EuroQol Group
Aug 29, 2002·Alimentary Pharmacology & Therapeutics·R D Cohen
Jan 22, 2003·The Cochrane Database of Systematic Reviews·A A AlfadhliB G Feagan
Sep 13, 2006·British Journal of Cancer·A LloydJ Watkins
Dec 13, 2006·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Lesley A GraffCharles N Bernstein
May 10, 2007·Gut·R SpillerUNKNOWN Clinical Services Committee of The British Society of Gastroenterology
May 30, 2007·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Martin J BuxtonRaymond J Townsend
Jul 14, 2007·Gastroenterology·F Reed JohnsonBruce E Sands
Sep 19, 2007·World Journal of Gastroenterology : WJG·Renato CavigliaMichele Cicala
Dec 7, 2007·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Inger Camilla SolbergUNKNOWN IBSEN Study Group
Oct 23, 2008·Health and Quality of Life Outcomes·Beenish NafeesJessamy Watkins
May 2, 2009·Inflammatory Bowel Diseases·Johan MestertonStefan Lindgren
May 15, 2009·Alimentary Pharmacology & Therapeutics·K BodgerD Hughes
May 28, 2009·The American Journal of Gastroenterology·Brian G FeaganStefan Schreiber
Jul 25, 2009·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Johanna HaapamäkiPerttu E T Arkkila
Dec 3, 2010·Journal of Crohn's & Colitis·J W HuamánF Guarner
Sep 1, 2007·Journal of Crohn's & Colitis·Subrata Ghosh, Rod Mitchell
Feb 1, 2009·Journal of Crohn's & Colitis·Ingrid BanovicJacques Cosnes
Jul 24, 2012·Journal of Crohn's & Colitis·François AubinDaniel Wendling
Sep 15, 2012·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Monia MarchettiGino R Corazza
Oct 19, 2012·The New England Journal of Medicine·William J SandbornUNKNOWN CERTIFI Study Group
Apr 18, 2013·Inflammatory Bowel Diseases·Asit ParikhBrian G Feagan
Apr 30, 2013·Journal of Medical Economics·S L ShinglerA J Lloyd
Oct 11, 2013·Gut·Keith BodgerUNKNOWN IBD Control Collaborative
Apr 22, 2015·Inflammatory Bowel Diseases·Emily K Wright, Michael A Kamm
Nov 2, 2015·Journal of Crohn's & Colitis·Annese VitoEbbe Langholz
Oct 8, 2016·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Sorrel E WolowaczRichard Norman
Aug 26, 2017·Frontline Gastroenterology·Jeanette WilburnStephen P McKenna